Romiplostim biosimilar (Qilu Pharmaceutical)

罗普司亭生物类似药（齐鲁制药）

Report date: 2026/04/28 20:00:22

Base Information

Drug NameRomiplostim biosimilar (Qilu Pharmaceutical)
Drug Alias Name罗普司亭生物类似药Recombinant human thrombopoietin mimetic-fusion protein (Qilu Pharmaceutical)注射用重组人血小板生成素拟肽-Fc融合蛋白（齐鲁制药）Romiplostim N01罗普司亭N01 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Aplastic
Global Approved IndicationsThrombocytopenia
Approved Indications in ChinaThrombocytopenia
Original Approved Country/TerritoryMainland China
Original Approved Date2024/04/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Aplastic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A